A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

NCT02268864 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Simeprevir
DRUG: Daclatasvir

Sponsor

Janssen-Cilag International NV